What factors do you use to decide between trastuzumab-deruxtecan and sacituzumab govitecan in HER2-low metastatic breast cancer?
Is there any data on the efficacy of T-Dxd after progression on sacituzumab govitecan?
Does your approach differ by hormone receptor status now that both agents have shown efficacy HR+ and HR- disease?
Answer from: Medical Oncologist at Academic Institution
There is currently limited data to guide the efficacy of T-DXd after progression on sacituzumab or vice versa. However, clinical trials to assess this are in development. Occhiogrosso Abelman et al. presented a small single institution study at ASCO 2023 suggesting that patients tended to have less ...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Deciding between trastuzumab-deruxtecan and sacituzumab govitecan in HER2-low metastatic breast cancer depends on various factors. Up until my knowledge cut-off in September 2021, no head-to-head trials were comparing these two therapies. The decision between these treatments might rely on the patie...
Answer from: Medical Oncologist at Community Practice
Tend to use T-Dxd in HER+ patients and sacituzumab in HER2 neg patients first.
Answer from: Medical Oncologist at Community Practice
Fam-trastuzumab deruxtecan (TDxd) and sacituzumab govitecan (SG) were and are being developed separately; in the course of their development, their paths collided leading to the key questions articulated above. There is no direct comparison between the 2 ADCs. The overarching hypotheses that led to ...